Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.

GlycoMimetics (GLYC) announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer ...